MX2022010449A - Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus. - Google Patents

Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus.

Info

Publication number
MX2022010449A
MX2022010449A MX2022010449A MX2022010449A MX2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A MX 2022010449 A MX2022010449 A MX 2022010449A
Authority
MX
Mexico
Prior art keywords
masp
coronavirus
respiratory distress
distress syndrome
acute respiratory
Prior art date
Application number
MX2022010449A
Other languages
English (en)
Inventor
Gregory A Demopulos
Tineka J Quinton
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2022010449A publication Critical patent/MX2022010449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrostatic Separation (AREA)

Abstract

En un aspecto, la invención proporciona métodos para tratar, inhibir, aliviar o prevenir el síndrome de dificultad respiratoria aguda, la neumonía o alguna otra manifestación pulmonar o de otro tipo de la infección por coronavirus, como la trombosis, en un sujeto mamífero infectado por coronavirus, como el SARS-CoV-2. Los métodos comprenden el paso de administrar a un sujeto infectado con coronavirus una cantidad de un agente inhibidor de MASP-2 eficaz para inhibir la activación del complemento dependiente de MASP-2. En una modalidad, el agente inhibidor de MASP-2 es un anticuerpo monoclonal de MASP-2, o un fragmento del mismo que se une específicamente a una porción de la SEQ ID NO:6. En una modalidad, el agente inhibidor de MASP-2 es un compuesto inhibidor de MASP-2 de molécula pequeña. En una modalidad, el sujeto es un sujeto humano que sufre el síndrome de dificultad respiratoria aguda (SDRA) inducido por COVID-19 y requiere oxígeno suplementario antes del tratamiento y el agente inhibidor de MASP-2 se administra en una cantidad suficiente para interrumpir la necesidad de oxígeno suplementario.
MX2022010449A 2020-03-06 2021-03-05 Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus. MX2022010449A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062986566P 2020-03-06 2020-03-06
US202063008540P 2020-04-10 2020-04-10
US202063015299P 2020-04-24 2020-04-24
US202063054298P 2020-07-21 2020-07-21
US202063062843P 2020-08-07 2020-08-07
US202063104229P 2020-10-22 2020-10-22
US202063105637P 2020-10-26 2020-10-26
US202163140591P 2021-01-22 2021-01-22
PCT/US2021/021217 WO2021178902A1 (en) 2020-03-06 2021-03-05 Methods of inhibiting masp-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
MX2022010449A true MX2022010449A (es) 2022-11-16

Family

ID=77614472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010449A MX2022010449A (es) 2020-03-06 2021-03-05 Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus.

Country Status (12)

Country Link
US (1) US20210292436A1 (es)
EP (1) EP4114522A4 (es)
JP (1) JP2023516727A (es)
KR (1) KR20220152554A (es)
CN (1) CN115335120A (es)
AU (1) AU2021231892A1 (es)
BR (1) BR112022016991A2 (es)
CA (1) CA3169034A1 (es)
IL (1) IL296240A (es)
MX (1) MX2022010449A (es)
TW (1) TW202319069A (es)
WO (1) WO2021178902A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
CN112023045A (zh) * 2020-03-31 2020-12-04 中国人民解放军军事科学院军事医学研究院 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof
WO2024081269A1 (en) * 2022-10-10 2024-04-18 Dixit Rohan Therapeutic combinations and methods to treat long covid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2446900T (lt) * 2004-06-10 2017-07-25 Omeros Corporation Ligų, susijusių su nuo masp-2 priklausomu komplemento aktyvavimu, gydymo būdai
KR101641057B1 (ko) * 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
CN109908352A (zh) * 2012-06-18 2019-06-21 奥默罗斯公司 抑制masp-1和/或masp-2和/或masp-3的组合物和方法
EP2920592A4 (en) * 2012-11-13 2016-07-06 Biogenius Llc COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY DISEASES OF INFECTIOUS AND NONINFFECTIVE ORIGIN
CN117964684A (zh) * 2018-05-29 2024-05-03 奥默罗斯公司 Masp-2抑制剂和使用方法
SG11202012627UA (en) * 2018-06-22 2021-01-28 Omeros Corp Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
CN112023045A (zh) * 2020-03-31 2020-12-04 中国人民解放军军事科学院军事医学研究院 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用

Also Published As

Publication number Publication date
EP4114522A4 (en) 2024-05-01
BR112022016991A2 (pt) 2022-12-06
WO2021178902A1 (en) 2021-09-10
EP4114522A1 (en) 2023-01-11
TW202146047A (zh) 2021-12-16
KR20220152554A (ko) 2022-11-16
IL296240A (en) 2022-11-01
AU2021231892A1 (en) 2022-10-20
TW202319069A (zh) 2023-05-16
US20210292436A1 (en) 2021-09-23
CA3169034A1 (en) 2021-09-10
JP2023516727A (ja) 2023-04-20
CN115335120A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
MX2022010449A (es) Métodos de inhibición de masp-2 para el tratamiento y/o prevención del síndrome de dificultad respiratoria aguda inducido por coronavirus.
Miesbach Pathological role of angiotensin II in severe COVID-19
Lupu et al. Crosstalk between the coagulation and complement systems in sepsis
Okroj et al. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
JP2019519584A5 (es)
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
Andrews et al. Treatments for COVID-19
MX2022000545A (es) Inhibidores de enzimas.
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
Smithies et al. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure
Meijers No contact, no thrombosis?
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
MX2023001481A (es) Metodos para tratar pacientes con hipercolesterolemia refractaria.
EA202192776A1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
Gerdin et al. Pulmonary Insufficiency in the Rat after Intravascular Coagulation and Inhibition of Fibrinolysis: I. Studies on Some Pathogenetic Mechanisms
MX2022000232A (es) Composiciones y metodos para tratar o evitar infecciones oculares con filociclovir.
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
AU2018244677A1 (en) Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane
MX2020002278A (es) Metodos para el tratamiento de enfermedades relacionadas con tnfa.
EA202190645A1 (ru) Ингибиторы калликреина плазмы и их применения для лечения приступа наследственного ангионевротического отека